The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2026 | Phase I study of ART-123, FOLFOX and bevacizumab in mCRC
Eli Gabayan, MD, Beverly Hills Cancer Center, Beverly Hills, CA, describes findings from a Phase I study (NCT05251727) evaluating ART-123, a recombinant soluble thrombomodulin, in combination with FOLFOX plus bevacizumab for metastatic colorectal cancer, with separate cohorts for patients with resected versus intact primary tumors. Across dose levels tested, ART-123 was safe and well tolerated, with low rates of bleeding events, none assessed as treatment related. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2026 Congress in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
